Investigational drug · Phase 3
Reference Drug
Also called: NSAIDs
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Retinal Vein Occlusion With Macular Edema, Knee Osteoarthritis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
1,606
Any phase or sponsor naming "Reference Drug"
First trial start
2025
Apr 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Reference Drug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinal Vein Occlusion With Macular Edema
- Knee Osteoarthritis
Approved drugs for the same conditions: Osteoarthritis · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Reference Drug" as an intervention, largest first.
Canadian Network for Observational Drug Effect Studies, CNODESAcademic, hospital or other
NCT02555852 · 4,238,504 participants · Start Sep 2011 · Primary completion Feb 2012
Drug: esomeprazole; omeprazole and 13 more · For: Gastroesophageal Reflux Disease (GERD); Community-acquired Pneumonia
Sites: Montreal, Canada
- Varenicline Pregnancy Cohort StudyCompleted
PfizerPfizer (PFE)
NCT01290445 · 885,185 participants · Start Sep 13, 2007 · Primary completion May 1, 2016
Drug: varenicline · For: Malformations
Brigham and Women's HospitalAcademic, hospital or other
NCT05794997 · 817,337 participants · Start Nov 30, 2022 · Primary completion Jan 1, 2023
Drug: Propranolol or Carvedilol; Atenolol, Bisoprolol or Sotalol · For: Hypertension
Sites: Boston, Massachusetts
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyActive, not recruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05220917 · 781,430 participants (planned) · Start Aug 1, 2021 · Primary completion May 31, 2026
Drug: SGLT2 inhibitor; DPP-4 inhibitor and 2 more · For: Cardiovascular Events; Type2 Diabetes; Renal Disease
Sites: Boston, Massachusetts
Brigham and Women's HospitalAcademic, hospital or other
NCT05768945 · 742,670 participants · Start Nov 30, 2022 · Primary completion Jul 7, 2023
Drug: Semaglutide; DPP-4 inhibitor · For: Diabetes
Sites: Boston, Massachusetts
Canadian Network for Observational Drug Effect Studies, CNODESAcademic, hospital or other
NCT02582736 · 725,489 participants · Start Apr 2012 · Primary completion Dec 2012
Drug: Olanzapine; Risperidone and 2 more · For: Psychotic Disorders; Schizophrenia; Schizoaffective Disorder and 2 more
Sites: Toronto, Canada
Brigham and Women's HospitalAcademic, hospital or other
NCT04746989 · 294,878 participants · Start Feb 1, 2021 · Primary completion Jul 17, 2023
Drug: Probenecid; Allopurinol · For: Gout
Sites: Boston, Massachusetts
AstraZenecaAstraZeneca (AZN)
NCT06099067 · 239,990 participants · Start May 15, 2020 · Primary completion Aug 31, 2023
Drug: Canagliflozin; DPP4 inhibitor and 3 more · For: Type 2 Diabetes Mellitus
Sites: Gothenburg, Sweden
Brigham and Women's HospitalAcademic, hospital or other
NCT03936049 · 168,690 participants · Start Sep 22, 2017 · Primary completion Feb 18, 2021
Drug: Liraglutide; DPP-4 inhibitor · For: Diabetes
Sites: Boston, Massachusetts
Brigham and Women's HospitalAcademic, hospital or other
NCT05125224 · 163,720 participants · Start Oct 1, 2021 · Primary completion Jul 7, 2023
Drug: Dihydropyridine calcium channel blocker; Hydrochlorothiazide · For: Hypertension
Sites: Boston, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
- In vitro and in vivo anthelmintic evaluation with molecular docking studies of bioactive compounds from Croton joufra Roxb.
Gogoi S, Yadav AK, Bihani M, et al. · J Ethnopharmacol 2027
- Computational identification of candidate ST2-binding bioactive compounds as putative modulators for severe type 2-high asthma.
Sun B, Li K, Ao D, et al. · Comput Biol Chem 2027
- Antihyperalgesic and antiallodynic effects of Salvia rosmarinus Spenn. extracts and some of their bioactive metabolites in a murine fibromyalgia pain model.
Siles-Guevara J, González-Trujano ME, Ovalle-Magallanes B, et al. · J Ethnopharmacol 2027
- Shoulder Arthritis.
Epner E, O'Brien D, LeClere LE, et al. · Clin Sports Med 2027
- Efficacy and safety study of diclofenac epolamine topical patch in accelerating rehabilitation of moderate hamstring strain: A randomized controlled trial.
Niu X, Zhang Z · Pak J Pharm Sci 2027
- AA and Male Fertility.
Das UN · Rev Physiol Biochem Pharmacol 2027
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.